Genital Herpes
Also known as: Herpes genitalis
Methodology & AI Transparency ⓘ
Genital Herpes Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Genital herpes is a sexually transmitted infection (STI) caused by a herpes simplex virus (HSV).
- 2 Real-world patient consensus: Synonyms for Genital Herpes (A60.9): Herpes genitalis (Infections & Antivirals).
- 3 Typical cash cost range: Clinicians assessing Genital Herpes focus on pathogen-associated molecular pattern in Genital Herpes (A60.9: (PAMP) innate immune) and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Genital Herpes: maintaining Complete Blood Count in Genital Herpes (A60.9: (WBC & Differential)) within WBC 4.0 – 10.0 x10^3/uL (A60.9).
Ask our AI Specialists anything about Genital Herpes
What Is Genital Herpes?
Genital herpes is a sexually transmitted infection (STI) caused by a herpes simplex virus (HSV). It can cause sores on your genital or rectal area, buttocks, and thighs. You can get it from having vaginal, anal, or oral sex with someone who has it. The virus can spread even when sores are not present. Mothers can also infect their babies during childbirth. Symptoms of herpes are called outbreaks. You usually get sores near the area where the virus has entered the body. The sores are blisters which break and become painful, and then heal. Sometimes people do not know they have herpes because they have no symptoms or very mild symptoms.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Genital Herpes (A60.9) features pathogen-associated molecular pattern in Genital Herpes (A60.9: (PAMP) innate immune). Cross-referenced with NIH MeSH (Herpes Genitalis), therapeutic stabilization in infections & antivirals is verified against C-Reactive Protein / in Genital Herpes (A60.9: Procalcitonin).
Common Symptoms & Clinical Signs
- • Presentation of Genital Herpes (A60.9): acute fever, chills, in Genital Herpes (A60.9: malaise, and myalgias)
- • Secondary Genital Herpes clinical sign: sore throat, productive in Genital Herpes (A60.9: cough, sinus/ear pain,)
- • Symptom flares in Genital Herpes correlating with Complete Blood Count in Genital Herpes (A60.9: (WBC & Differential)) deviation outside WBC 4.0 – 10.0 x10^3/uL (A60.9)
- • Functional infections & antivirals impact requiring bacterial/fungal culture with in Genital Herpes (A60.9: antimicrobial susceptibility testing) evaluation (A60.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Genital Herpes Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | A60.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Complete Blood Count in Genital Herpes (A60.9: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (A60.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: C-Reactive Protein / in Genital Herpes (A60.9: Procalcitonin) | Resolution to baseline (A60.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Targeted PCR / in Genital Herpes (A60.9: Culture & Sensitivity) | Pathogen clearance / negative test (A60.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Genital Herpes
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Acyclovir Zovirax, Avaclyr • RxCUI 197311 | Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor | 78% | $0.0962 | $ 6.30 /mo |
| Herz Homo (Herpes Zoster Nosode) Herz Homo • RxCUI RXN-B437421889 | Over-the-Counter Clinical Monograph | 86% | $2.3700 | $ 179.14 /mo |
| Lidocaine and Prilocaine Oraqix • RxCUI 197877 | Amide Local Anesthetic | 90% | $0.2164 | $ 17.26 /mo |
| Acyclovir and Hydrocortisone Xerese • RxCUI 998422 | Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor | 84% | $0.1070 | $ 12.83 /mo |
| Xerese (Acyclovir and Hydrocortisone) Xerese • RxCUI 998426 | Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor | 93% | $0.1070 | $ 16.21 /mo |
| Hers Homo (Herpes Simplex I, Herpes Simplex Ii) Hers Homo • RxCUI RXN-B437421875 | Over-the-Counter Clinical Monograph | 88% | $2.6700 | $ 200.74 /mo |
| Zovirax (Acyclovir) Zovirax • RxCUI 307730-B01870994 | Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor | 77% | $0.1070 | $ 6.30 /mo |
| Famciclovir Famvir • RxCUI 198382 | Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor | 93% | $0.2120 | $ 10.46 /mo |
| Acyclovir Sodium Zovirax • RxCUI 1734932 | Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor | 80% | $0.1070 | $ 6.30 /mo |
| Valtrex (Valacyclovir Hydrochloride) Valtrex • RxCUI 313565-B01730933 | Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor | 83% | $12.8051 | $ 9.27 /mo |
| Avaclyr (Acyclovir) Avaclyr • RxCUI 197311-B48102028 | Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor | 93% | $0.1070 | $ 16.21 /mo |
| Podophyllum Resin Podocon 25 • RxCUI RXN-713352925-1790 | FDA Prescription Therapeutic Agent | 87% | $2.1900 | $ 97.20 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Genital Herpes)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Sildenafil for congenital heart diseases induced lung high blood pressure, a: What a 849-Participant Study Found Sildenafil is a well-tolerated treatment in congenital heart diseases induced lung high blood pressure, as it has proven its efficacy not only in lowering both PAP mean and systolic but also in reducing the ventilation time,... BMC pediatrics • 2023-07-20 • Meta-Analysis | N = 849 | 97/100 | PMID 37474896 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of apremilast in patients with moderate-to-severe genital Apremilast demonstrated statistically and clinically meaningful genital Physician Global Assessment responses and improvement of signs, symptoms, severity, and quality of life in this first randomized, controlled study of an... Journal of the American Academy of Dermatology • 2024-03-15 • Phase III Randomized Trial | N = 143 | 88/100 | PMID 37852306 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Naftifine Hydrochloride 2% Gel in Interdigital Tinea Naftifine 2% gel was efficacious and safe for the treatment of mild to moderate interdigital tinea pedis. Clinical drug investigation • 2023-07-15 • Phase III Randomized Trial | N = 112 | 88/100 | PMID 37462803 ↗ |
| Can This Approach Help? Inside the Latest Research on Validation of a Health-Related Quality of Life Questionnaire in Patients With Cdiff32 is a valid, reliable, and responsive disease-specific HRQOL questionnaire that is fit for purpose for interventional treatment trials. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2023-02-08 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35789381 ↗ |
| Can This Approach Help? Inside the Latest Research on Switching Patients With Congenital Adrenal Hyperplasia to Modified-Release MRHC showed comparable bioavailability to IRHC based on cortisol AUC after 20 mg administration. Clinical endocrinology • 2025-09-15 • Phase III Randomized Trial | N = 63 | 82/100 | PMID 40377230 ↗ |
Genital Herpes Patient Community & “People Like Me” Threads
Filter Genital Herpes community threads and patient logs by age, biological sex, dosage, and treatment duration.